Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.